Physician profile
Ethiraj Raj
NPI 1376532556
$7,902.04
in general payments reported to CMS, 2019-2025
32 companies · $42.10 in 2025
The $42.10 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,974 · 2020: $585 · 2021: $709 · 2022: $917 · 2023: $1,372 · 2024: $1,303 · 2025: $42.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,717.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $1,719.58 | 2019-2023 | Ffrct |
| Novartis Pharmaceuticals Corporation | $1,218.33 | 2019-2025 | |
| Amgen INC. | $1,071.64 | 2019-2024 | Repatha |
| Astellas Pharma US INC | $435.27 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $410.05 | 2021-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $406.07 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $380.42 | 2019-2024 | Eliquis, Camzyos |
| Pfizer INC. | $328.27 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.99 | 2021-2024 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $177.68 | 2019-2024 | Uptravi, Opsumit |
| Abbott Laboratories | $173.18 | 2019-2024 | Cardiomems |
| Esperion Therapeutics, INC. | $140.73 | 2020-2024 | Nexletol |
| Kiniksa Pharmaceuticals, LTD. | $129.33 | 2021-2023 | Arcalyst |
| Kestra Medical Technology Services, INC. | $121.17 | 2023-2024 | Assure Wcd |
| Medtronic Vascular, INC. | $118.12 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $117.99 | 2020-2023 | Onpattro |
| Kiniksa Pharmaceuticals International, Plc | $115.19 | 2024 | Arcalyst |
| Boston Scientific Corporation | $114.52 | 2019-2024 | Sq-Rx Pulse Generator |
| Regeneron Healthcare Solutions, INC. | $81.05 | 2019 | |
| Sanofi-Aventis U.S. LLC | $71.08 | 2019-2024 | |
| Teleflex LLC | $53.48 | 2022-2023 | Manta, Turnpike |
| Vital Connect, INC | $40.13 | 2024 | Vitalpatch Rtm |
| Lexicon Pharmaceuticals, INC. | $35.62 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $32.66 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.79 | 2023 | |
| Genzyme Corporation | $20.86 | 2019 | |
| Philips North America LLC | $19.34 | 2024 | (Ck4) Mcot |
| Medicomp INC | $17.89 | 2019 | |
| Vifor Pharma, INC. | $16.17 | 2020 | |
| Medtronic, INC. | $15.78 | 2022 | |
| Terumo Medical Corporation | $14.84 | 2019 | |
| Novo Nordisk INC | $12.82 | 2023 | Rybelsus, Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ethiraj Raj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.